company background image
CORT logo

Corcept Therapeutics NasdaqCM:CORT Stock Report

Last Price

US$24.06

Market Cap

US$2.5b

7D

7.2%

1Y

25.3%

Updated

03 Mar, 2024

Data

Company Financials +

Corcept Therapeutics Incorporated

NasdaqCM:CORT Stock Report

Market Cap: US$2.5b

CORT Stock Overview

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.

CORT fundamental analysis
Snowflake Score
Valuation5/6
Future Growth4/6
Past Performance5/6
Financial Health6/6
Dividends0/6

Corcept Therapeutics Incorporated Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Corcept Therapeutics
Historical stock prices
Current Share PriceUS$24.06
52 Week HighUS$34.28
52 Week LowUS$20.45
Beta0.46
1 Month Change11.49%
3 Month Change-8.38%
1 Year Change25.31%
3 Year Change-2.00%
5 Year Change99.01%
Change since IPO96.73%

Recent News & Updates

We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Feb 22
We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Corcept Therapeutics: Key Catalysts Ahead

Feb 19

Recent updates

We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Feb 22
We Like Corcept Therapeutics' (NASDAQ:CORT) Earnings For More Than Just Statutory Profit

Corcept Therapeutics: Key Catalysts Ahead

Feb 19

After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar

Dec 23
After Leaping 29% Corcept Therapeutics Incorporated (NASDAQ:CORT) Shares Are Not Flying Under The Radar

Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price

Nov 07
Corcept Therapeutics Incorporated's (NASDAQ:CORT) Intrinsic Value Is Potentially 59% Above Its Share Price

Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?

Jun 23
Are Corcept Therapeutics Incorporated (NASDAQ:CORT) Investors Paying Above The Intrinsic Value?

Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)

Feb 16
Estimating The Intrinsic Value Of Corcept Therapeutics Incorporated (NASDAQ:CORT)

Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Might Deserve Your Attention Today

Jan 11
Here's Why We Think Corcept Therapeutics (NASDAQ:CORT) Might Deserve Your Attention Today

Corcept Therapeutics starts phase 2 trial of its ALS treatment

Oct 11

Does Corcept Therapeutics (NASDAQ:CORT) Deserve A Spot On Your Watchlist?

Sep 27
Does Corcept Therapeutics (NASDAQ:CORT) Deserve A Spot On Your Watchlist?

Corcept extends distribution agreement for Cushing’s syndrome drug

Sep 23

Corcept Therapeutics: A Status Check

Sep 06

Corcept cut to Hold at Truist on balanced risk-reward setup

Aug 01

Corcept Therapeutics begins phase 3 trial of relacorilant for ovarian cancer

Jun 29

I Ran A Stock Scan For Earnings Growth And Corcept Therapeutics (NASDAQ:CORT) Passed With Ease

Jun 09
I Ran A Stock Scan For Earnings Growth And Corcept Therapeutics (NASDAQ:CORT) Passed With Ease

Is Now The Time To Put Corcept Therapeutics (NASDAQ:CORT) On Your Watchlist?

Feb 23
Is Now The Time To Put Corcept Therapeutics (NASDAQ:CORT) On Your Watchlist?

An Intrinsic Calculation For Corcept Therapeutics Incorporated (NASDAQ:CORT) Suggests It's 47% Undervalued

Nov 13
An Intrinsic Calculation For Corcept Therapeutics Incorporated (NASDAQ:CORT) Suggests It's 47% Undervalued

Shareholder Returns

CORTUS PharmaceuticalsUS Market
7D7.2%-0.4%1.2%
1Y25.3%25.0%24.4%

Return vs Industry: CORT exceeded the US Pharmaceuticals industry which returned 24.2% over the past year.

Return vs Market: CORT exceeded the US Market which returned 24.2% over the past year.

Price Volatility

Is CORT's price volatile compared to industry and market?
CORT volatility
CORT Average Weekly Movement10.9%
Pharmaceuticals Industry Average Movement9.7%
Market Average Movement6.1%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: CORT's share price has been volatile over the past 3 months.

Volatility Over Time: CORT's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1998352Joseph Belanoffhttps://www.corcept.com

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing’s syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors.

Corcept Therapeutics Incorporated Fundamentals Summary

How do Corcept Therapeutics's earnings and revenue compare to its market cap?
CORT fundamental statistics
Market capUS$2.49b
Earnings (TTM)US$105.50m
Revenue (TTM)US$482.38m

23.6x

P/E Ratio

5.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CORT income statement (TTM)
RevenueUS$482.38m
Cost of RevenueUS$6.48m
Gross ProfitUS$475.89m
Other ExpensesUS$370.40m
EarningsUS$105.50m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)1.02
Gross Margin98.66%
Net Profit Margin21.87%
Debt/Equity Ratio0%

How did CORT perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.